0%
Print report
Variant interpretation report

WFS1 c.2327A>T, p.Glu776Val

NM_006005.3:c.2327A>T NP_005996.2:p.(Glu776Val) Missense · exon 8 View identifiers
Classification
Uncertain significance

Variant description:

The WFS1 NM_006005.3:c.2327A>T (NP_005996.2:p.(Glu776Val)) missense variant has not previously been reported in somatic cancers (COSMIC). Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About WFS1

WFS1 encodes wolframin, a transmembrane protein found mainly in the endoplasmic reticulum and involved in the function of cells such as pancreatic beta cells and neurons. Changes in WFS1 can cause Wolfram syndrome, an inherited disorder characterized by diabetes mellitus, optic atrophy, hearing loss, and other neurological problems, as well as autosomal dominant nonsyndromic deafness. WFS1 has no established role in cancer.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is Generic ACMG/AMP 2015 with ClinGen SVI recommendations. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 1 Benign evidence criteria: 1
Pathogenic criteria applied · 1
PP3Strong
PP3 · strong

Met, strong: missense REVEL score 0.981 exceeds the generic PP3 strong threshold of 0.932.

Benign criteria applied · 1
BS4Strong
BS4 · strong

Met, strong: p.Glu776Val did not segregate with hearing impairment in the studied families, although complete pedigree details require review.

Recorded classification: Uncertain significance

VUS: PP3 strong and BS4 strong are conflicting directional evidence, but neither side meets a generic ACMG/AMP pathogenic or benign combination rule.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
6,835 / 1,612,924 alleles

gnomAD v4.1: 6,835 / 1,612,924 alleles. Recorded AF 0.00423765. Recorded homozygote count 31.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 0.00377959; MAF= 0.37796%, 1054/278866 alleles, homozygotes = 2) and has highest observed frequency in the European (Finnish) population (AF= 0.0102049; MAF= 1.02049%, 256/25086 alleles, homozygotes = 1); grpmax FAF= 0.00511863.

gnomAD-Canada

Not available in gnomAD-Canada v1.0.

No screenshot for this evidence
REVEL score
0.981 recorded score

Recorded REVEL score: 0.981. Refer to the recorded PP3/BP4 rationale for interpretation.

ClinVar submissions
17 reported laboratory submissions

10 Likely benign · 6 Benign · 1 Likely Benign. ClinVar API review status: criteria provided, multiple submitters, no conflicts.

Context only ClinVar ↗
No screenshot for this evidence
Functional evidence
Not recorded

No standalone functional evidence summary is recorded in evidence_summary.functional.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
No matching record reported

This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under Generic ACMG/AMP 2015 with ClinGen SVI recommendations, with the data and sources behind each one.

28 criteria with recorded statuses: 2 met · 14 not met · 8 not assessed · 4 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

No variant-specific validated functional assay supporting either a damaging or a normal functional effect was identified.

PS3 and BS3 are therefore both not_assessed; clinical, inheritance, computational, and population evidence was not used for these functional criteria.

No VCEP covers WFS1 in this case; generic ACMG/AMP 2015 rules govern.

No PS4 case-control estimate, PP4-specific phenotype, or BP5 alternate molecular diagnosis was available for assessment.

PP5 and BP6 were not triggered because the exact-variant ClinVar record has zero expert-panel submissions and ordinary laboratory submissions are excluded by the specified rule.

This missense variant is assessed on the REVEL-only computational path under the generic ACMG/AMP rules.

REVEL 0.981 supports PP3 at strong strength and does not support BP4; SpliceAI and BayesDel are not used to override that path selection.

Met · 2

PP3 StrongACMGMet, strong: missense REVEL score 0.981 exceeds the generic PP3 strong threshold of 0.932. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, so the generic PP3 missense path uses REVEL only; SpliceAI and BayesDel are not used for this criterion. REVEL is 0.981, meeting the supplied generic PP3 strong threshold of >= 0.932 from the ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet, PMID:36413997). This supports PP3 at strong strength without double-counting additional computational predictors.

Rule
PP3: Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.).
Evidence considered
  • Variant consequence: missense, NP_005996.2:p.(Glu776Val); therefore the applicable generic PP3 path is REVEL only.
  • Local REVEL lookup reports score 0.981 for NM_006005.3:c.2327A>T (source_registry key: revel).
  • Generic calibration: PP3 strong requires REVEL >= 0.932 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet), PMID:36413997.
  • SpliceAI max delta is 0.001 and BayesDel is 0.51747, but neither is used because this is a missense variant and the governing generic path requires REVEL only.
Sources
revel
BS4 StrongACMG_2015Met, strong: p.Glu776Val did not segregate with hearing impairment in the studied families, although complete pedigree details require review. Details ▾Hide ▴
Reasoning

BS4 is met at the generic ACMG/AMP strong benign level. The PubMed abstract for the variant-specific hearing-loss study states that p.Glu776Val did not segregate with hearing impairment in the families. A second full-text source reports maternal inheritance and identifies BS4 in its benign reanalysis. Human review is retained because the available evidence does not provide the complete pedigree, affected-member count, or detailed assessment of phenocopy and alternative genetic causes.

Rule
Lack of segregation in affected members of a family. Caveat: The presence of phenocopies for common phenotypes (i.e. cancer, epilepsy) can mimic lack of segregation among affected individuals.
Evidence considered
  • PMID:24909696, abstract; detailed pedigree referenced as family C: "The other two rare variants, p.Glu385Lys and p.Glu776Val, did not segregate with HI in the families."
  • PMID:34997062, Table 2, row 17 and reclassification discussion: p.(Glu776Val) was maternally inherited, and the authors' benign reanalysis included BS4.
Still missing
  • The complete family pedigree, number of affected and unaffected tested relatives, and details excluding phenocopies or additional pathogenic variants were not available in the reviewed extracts.
Sources

Not met · 14 · evaluated, threshold not reached

PS1 ACMG_2015Not met: WFS1 p.Glu776Val is reported as benign or likely benign, with no previously established pathogenic variant producing the same amino-acid change. Details ▾Hide ▴
Reasoning

PS1 is not met. The observed variant is WFS1 p.Glu776Val (c.2327A>T), and the available evidence identifies it as benign or likely benign rather than as a previously established pathogenic amino-acid change. No previously established pathogenic variant producing the same p.Glu776Val substitution is documented in the reviewed evidence. The exact variant is reported as benign after reanalysis in PMID:34997062 and as benign/likely benign by multiple ClinVar submitters.

Rule
Same amino acid change as a previously established pathogenic variant regardless of nucleotide change.
Evidence considered
  • ClinVar variation 166606 reports WFS1 p.Glu776Val as Likely benign from 10 laboratories, Benign from 6, and Likely Benign from 1, with multiple submitters and no conflicts.
  • PMID:34997062 reports p.(Glu776Val) and states that it changed from conflicting interpretation to benign after reanalysis; no pathogenic same-amino-acid comparator is established.
Sources
PS2 ACMG_2015Not met: the variant was maternally inherited, not observed as de novo with confirmed maternity and paternity. Details ▾Hide ▴
Reasoning

PS2 is not met. The variant was reported as maternally inherited in a hearing-loss cohort, which is inconsistent with a de novo observation; no evidence shows confirmed maternity and paternity with absence of a family history.

Rule
De novo (both maternity and paternity confirmed) in a patient with the disease and no family history.
Evidence considered
  • PMID:34997062, Table 2, WFS1 p.(Glu776Val) entry: the variant was reported with maternal inheritance in a patient with bilateral, moderate, progressive hearing loss.
  • PMID:34997062, study context: whole-exome sequencing with Sanger confirmation and family segregation analysis when available.
Sources
PM1 ACMG_2015Not met: residue 776 has no documented critical functional domain or qualifying hotspot, and the available C-terminal regional observation is not a defined PM1 domain. Details ▾Hide ▴
Reasoning

PM1 is not met. No VCEP domain table applies to WFS1, and the reviewed evidence provides no WFS1-approved critical functional domain, active site, or named hotspot route covering residue 776. PMID:26435059 discusses the C-terminal hydrophilic part of WFS1 as a region containing many reported missense mutations, but does not establish residue 776 as a critical functional domain or hotspot without benign variation. The case hotspot and COSMIC results are negative.

Rule
Located in a mutational hot spot and/or critical and well-established functional domain (e.g. active site of an enzyme) without benign variation.
Evidence considered
  • vcep_materials.json has no WFS1 domain-table entry or VCEP-specific PM1 specification.
  • Cancer Hotspots reports that the variant does not lie in a statistically significant hotspot; COSMIC reports no prior somatic cancer observation.
  • PMID:26435059 describes a C-terminal hydrophilic region with many missense mutations but does not designate residue 776 as a critical domain or establish absent benign variation.
Sources
PM2 ACMG_2015Not met: the variant's all-comers gnomAD AF is 0.004237645419127001, exceeding the PM2 threshold of 0.0001. Details ▾Hide ▴
Reasoning

PM2 is not met. No governing non-cancer or exome-only source was specified, so all-comers gnomAD data are used. The variant is present at AF 0.0037795930662038396 in gnomAD v2.1 and AF 0.004237645419127001 in gnomAD v4.1, both above the supplied PM2 supporting threshold of <=0.0001; it is therefore neither absent nor at an extremely low frequency in controls.

Rule
Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • gnomAD v2.1 all-comers: AF 0.0037795930662038396, 1054/278866 alleles, 2 homozygotes.
  • gnomAD v4.1 all-comers: AF 0.004237645419127001, 6835/1612924 alleles, 31 homozygotes.
  • The supplied generic PM2 supporting threshold is <=0.0001; the variant exceeds it in both available all-comers datasets.
Sources
PM5 ACMG_2015Not met: the only same-residue comparator, E776K, is computationally predicted damaging but not established pathogenic. Details ▾Hide ▴
Reasoning

PM5 is not met. PMID:37185285 reports a different substitution at the same residue, WFS1 E776K, but describes it as a novel missense variant supported by computational predictions, not as a previously established pathogenic variant. Therefore, E776K does not satisfy the pathogenic comparator required for PM5. The observed p.Glu776Val variant itself is reported as benign or likely benign.

Rule
Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before.
Evidence considered
  • PMID:37185285 reports WFS1 E776K as a novel missense variant with in-silico conservation, stability, and structural predictions, but no established pathogenic clinical or functional evidence.
  • ClinVar variation 166606 reports the observed p.Glu776Val as benign/likely benign.
Sources
PM6 ACMG_2015Not met: maternal inheritance was reported, so the evidence does not support an assumed de novo occurrence without parental confirmation. Details ▾Hide ▴
Reasoning

PM6 is not met. The available variant-specific evidence reports maternal inheritance rather than an assumed de novo occurrence; therefore the required de novo observation without parental confirmation is absent.

Rule
Assumed de novo, but without confirmation of paternity and maternity.
Evidence considered
  • PMID:34997062, Table 2, WFS1 p.(Glu776Val) entry: the variant was reported as maternally inherited.
  • No source reviewed for this criterion reports the variant as de novo with unconfirmed maternity and paternity.
Sources
PP1 ACMG_2015Not met: p.Glu776Val did not segregate with hearing impairment in the studied families, so co-segregation is not demonstrated. Details ▾Hide ▴
Reasoning

PP1 is not met. The variant-specific literature states that p.Glu776Val did not segregate with hearing impairment in the studied families, providing non-segregation rather than co-segregation with affected family members.

Rule
Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease. Note: May be used as stronger evidence with increasing segregation data.
Evidence considered
  • PMID:24909696, abstract: p.Glu776Val did not segregate with hearing impairment in the families.
  • PMID:34997062, Table 2 and reclassification discussion: p.(Glu776Val) was maternally inherited and the authors' reanalysis listed PP1_Sup and BS4 in a benign classification; this secondary classification is consistent with non-segregation, not independent co-segregation evidence.
Sources
PP2 ACMG_2015Not met: WFS1 p.Glu776Val has gnomAD v4.1 allele frequency 0.00423765 and benign ClinVar submissions, arguing against a low benign-missense rate. Details ▾Hide ▴
Reasoning

PP2 is not met. The required combination is not supported for WFS1: the gene shows substantial benign missense variation, including this p.Glu776Val variant with gnomAD v4.1 allele frequency 0.00423765 and ClinVar benign/likely benign submissions, so a low rate of benign missense variation is not established. Although WFS1 disease databases contain many missense variants, the reviewed evidence does not establish both PP2 requirements under the generic definition.

Rule
Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.
Evidence considered
  • gnomAD v4.1 reports allele frequency 0.00423765 (6835/1612924 alleles), 31 homozygotes, and Finnish population AF 0.0112445.
  • ClinVar variation 166606 reports the exact missense variant as Benign or Likely benign across multiple submitters.
  • PMID:28432734 reports 156 WFS1 missense variants among 309 database variants but also benign/likely benign and uncertain variants, not a low benign-missense rate.
Sources
PP5 ACMG_2015Not met: ClinVar has 0 expert-panel submissions for the exact variant, and no reviewed source reports it as pathogenic under PP5. Details ▾Hide ▴
Reasoning

PP5 is not met because the exact-variant ClinVar record has zero expert-panel submissions. Its 18 submissions are ordinary laboratory or research submissions, including benign and likely benign classifications, and therefore cannot trigger PP5 under the stated rule. The benign reanalysis in PMID:34997062 also does not report the variant as pathogenic.

Rule
Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • The exact ClinVar variation NM_006005.3(WFS1):c.2327A>T (p.Glu776Val) has 18 submissions and 0 expert-panel submissions; the recorded classifications are benign or likely benign from ordinary submitters.
  • PMID:34997062 reports that p.(Glu776Val) was changed from conflicting interpretation to benign, not pathogenic.
Sources
BA1 ACMGNot met: gnomAD grpmax FAF is 0.00511863 at most, below the 0.05 BA1 threshold despite a higher Finnish popmax point estimate. Details ▾Hide ▴
Reasoning

BA1 is not met. No governing non-cancer or exome-only source was specified, so the all-comers gnomAD data are used. The required FILTERING allele-frequency measure, grpmax FAF, is 0.00511863 in gnomAD v2.1 and 0.0046733 in gnomAD v4.1, both below the generic stand-alone threshold of 0.05. The Finnish populations supplying the highest observed frequencies have 25,086 and 62,786 observed alleles, respectively, so the minimum 2,000-allele population-size requirement is satisfied; the higher Finnish popmax point estimates are not used for BA1.

Rule
Allele frequency is above 5% in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • gnomAD v2.1 all-comers: total AF 0.0037795930662038396 (1054/278866 alleles; 2 homozygotes), Finnish popmax AF 0.010204895160647372 (256/25086 alleles), grpmax FAF 0.00511863.
  • gnomAD v4.1 all-comers: total AF 0.004237645419127001 (6835/1612924 alleles; 31 homozygotes), Finnish popmax AF 0.011244544962252731 (706/62786 alleles), grpmax FAF 0.0046733.
  • The generic BA1 calibration supplied for this case is >=0.05; ClinGen SVI frequency guidance requires using filtering allele frequency rather than the popmax point estimate, and the qualifying population must have at least 2,000 observed alleles.
Sources
BS1 ACMGNot met: the qualifying gnomAD grpmax FAF is 0.00511863, below the generic BS1 threshold of 0.01; Finnish popmax point estimates are not used. Details ▾Hide ▴
Reasoning

BS1 is not met on the supplied generic threshold. No non-cancer or exome-only source was specified, so all-comers gnomAD data are used. The required filtering measure, grpmax FAF, is 0.00511863 in gnomAD v2.1 and 0.0046733 in gnomAD v4.1, both below the generic default threshold of 0.01. These values are based on populations with more than 2,000 observed alleles; the Finnish popmax point estimates of 0.010204895160647372 and 0.011244544962252731 are not used. Because the observed FAF does not exceed 0.01, no maximum-credible-frequency calculation is needed to reject the default BS1 path.

Rule
Allele frequency is greater than expected for the disorder.
Evidence considered
  • gnomAD v2.1 all-comers: grpmax FAF 0.00511863; Finnish popmax AF 0.010204895160647372 from 256/25086 alleles.
  • gnomAD v4.1 all-comers: grpmax FAF 0.0046733; Finnish popmax AF 0.011244544962252731 from 706/62786 alleles.
  • The generic BS1 default supplied for this case is >=0.01. Whiffin et al. 2017 (PMID:28518168) supports considering prevalence, penetrance, and allelic heterogeneity before applying a generic frequency threshold, but the observed filtering AF is already below the default threshold.
  • The qualifying population sizes exceed 2,000 observed alleles; the lower-bound FAF, not the Finnish popmax point estimate, is the adjudicated frequency figure.
Sources
BP1 ACMG_2015Not met: WFS1 has a substantial documented missense disease mechanism, including C-terminal missense variants, rather than primarily truncating disease causation. Details ▾Hide ▴
Reasoning

BP1 is not met. WFS1 disease is not characterized in the reviewed evidence as being caused primarily by truncating variants to the exclusion of missense disease mechanisms. PMID:28432734 reports a large WFS1 missense-variant set and specifically classifies C-terminal missense variants as a disease-related genotype group, while PMID:31638168 describes WFS1 missense variants in a monogenic-diabetes cohort. The gene-level pattern therefore does not support BP1.

Rule
Missense variant in a gene for which primarily truncating variants are known to cause disease.
Evidence considered
  • PMID:28432734 reports 156 WFS1 missense variants among 309 database variants and defines C-terminal missense variants as group 2 variants associated with minor loss of function.
  • PMID:31638168 reports WFS1 missense variants in children evaluated for monogenic diabetes and discusses heterozygous WFS1 variants in relation to early-onset diabetes risk.
Sources
BP4 ACMGNot met: REVEL 0.981 is above the generic BP4 supporting threshold of 0.29, so it does not indicate a tolerated missense change. Details ▾Hide ▴
Reasoning

The variant is a missense change, so BP4 must use the REVEL path only. REVEL is 0.981, which is above the generic BP4 supporting threshold of <= 0.29 and therefore does not support no impact. The SpliceAI max delta of 0.001 is not used for BP4 because no-predicted-splice-impact is not BP4 evidence for a missense variant; BayesDel is not available for generic ACMG strength assignment.

Rule
Missense variant -> REVEL only. Its SpliceAI score says nothing about whether the amino-acid substitution is tolerated, so 'no predicted splice impact' is never BP4 support for a missense variant. BP4 (supporting): <= 0.29 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • NM_006005.3:c.2327A>T is a missense variant, so BP4 uses REVEL only.
  • Local REVEL lookup reports a score of 0.981 for this variant.
  • The generic BP4 supporting threshold is <= 0.29, from the ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet; PMID:36413997).
  • SpliceAI max delta 0.001 was not substituted for the missense REVEL result, and BayesDel 0.51747 is not available for generic ACMG-strength assignment.
Sources
revel
BP6 ACMG_2015Not met: no exact-variant ClinVar expert-panel benign or likely-benign classification exists, and the published benign interpretation is independently available. Details ▾Hide ▴
Reasoning

BP6 is not met because the exact-variant ClinVar record contains no expert-panel classification. The record contains only ordinary laboratory or research submissions, and those submissions cannot trigger BP6 under the stated generic rule. In addition, the benign interpretation in PMID:34997062 is available for independent review rather than being unavailable evidence.

Rule
Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • The exact ClinVar record has 0 expert-panel submissions; its benign and likely-benign classifications are from ordinary laboratory or research submissions.
  • PMID:34997062 reports the exact p.(Glu776Val) variant and describes a benign reanalysis, so that source is available for independent evaluation rather than unavailable evidence.
Sources

Not assessed · 8 · no assessment recorded

PS3 ACMG_2015Not assessed: no variant-specific validated functional assay showing a damaging effect was identified for WFS1 p.Glu776Val. Details ▾Hide ▴
Reasoning

No variant-specific validated in vitro or in vivo functional assay for NM_006005.3:c.2327A>T (NP_005996.2:p.(Glu776Val)) was identified in the reviewed evidence. PMID:26435059 evaluated WFS1 nonsynonymous variants with computational prediction and structural modeling, but did not mention p.Glu776Val and reported no variant-specific experimental assay. PMID:34997062 reported the exact variant in a hearing-loss cohort, but its evidence was sequencing, inheritance, and curation rather than a functional experiment. Therefore, the required evidence supporting a damaging effect is absent, and PS3 remains not_assessed rather than not_met.

Rule
Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product.
Evidence considered
  • PMID:26435059, Discussion: the study used computational prediction and structural analyses of WFS1 nonsynonymous variants; it did not mention c.2327A>T or p.Glu776Val and reported no variant-specific functional assay.
  • PMID:34997062, Results/Variant curation and Table 2, WFS1 variant 17: the exact p.(Glu776Val) variant was identified by whole-exome sequencing and assessed with inheritance and variant-curation evidence, but no functional assay result was reported.
  • No reviewed source supplied a validated, reproducible, variant-specific in vitro or in vivo result demonstrating a damaging effect on WFS1 protein function or splicing.
Still missing
  • No variant-specific in vitro or in vivo assay result was identified for NM_006005.3:c.2327A>T (p.Glu776Val).
  • No assay validation, control performance, reproducibility data, or quantitative functional measurement is available for this variant.
Sources
PS4 ACMG_2015Not assessed: no case-control counts or odds ratio with a 95% confidence interval were available to test the PS4 >5.0 and CI-excludes-1.0 requirement. Details ▾Hide ▴
Reasoning

PS4 requires a case-control prevalence comparison with an odds ratio or relative risk >5.0 and a 95% confidence interval that excludes 1.0. The literature_pass packet has no ai_classified_papers, and its PS4-indexed records (PMID:20301607 and PMID:20301750) provide no documented exact-variant case and control counts in the supplied evidence. PMID:24909696 reports that p.Glu776Val did not segregate with hearing impairment, and PMID:34997062 reports the exact variant in a hearing-loss patient and a benign reanalysis, but neither supplies a case-control enrichment estimate. Therefore the required numerical comparison cannot be calculated and PS4 is not assessed.

Rule
The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls. ... Relative risk (RR) or odds ratio (OR), as obtained from case-control studies, is >5.0 and the confidence interval around the estimate of RR or OR does not include 1.0.
Evidence considered
  • The literature_pass PS4 index listed PMID:20301607 and PMID:20301750, but ai_classified_papers was empty and no case-control counts or effect estimate were documented for either record.
  • PMID:24909696 states: "The other two rare variants, p.Glu385Lys and p.Glu776Val, did not segregate with HI in the families." This is familial segregation evidence, not a case-control prevalence comparison.
  • PMID:34997062 reports NM_006005.3:c.2327A>T, p.(Glu776Val), in a hearing-loss patient and describes benign reanalysis, but does not provide affected-versus-unaffected control counts for this exact variant.
Still missing
  • A case-control study or matched-ancestry case frequency and control frequency for NM_006005.3:c.2327A>T is needed to calculate OR/RR and its 95% confidence interval.
Sources
PM3 ACMG_2015Not assessed: maternal inheritance is reported, but no affected proband has a documented pathogenic WFS1 allele in trans with phase established. Details ▾Hide ▴
Reasoning

PM3 is not assessed. The exact variant NM_006005.3:c.2327A>T (NP_005996.2:p.(Glu776Val)) was reported with maternal inheritance, but the available evidence does not document an affected proband carrying a known pathogenic WFS1 variant in trans, and no parental or offspring testing establishes phase with such a variant. The available segregation report instead states that p.Glu776Val did not segregate with hearing impairment, which does not satisfy the recessive trans configuration required for PM3.

Rule
For recessive disorders, detected in trans with a pathogenic variant.
Evidence considered
  • PMID:34997062, Table 2, WFS1 entry for p.(Glu776Val): the variant is reported with maternal inheritance, but the cited record does not document a known pathogenic WFS1 allele in trans or phase with one.
  • PMID:24909696, abstract: p.Glu776Val did not segregate with hearing impairment in the studied families; this does not establish a pathogenic allele in trans or the phase required for PM3.
Still missing
  • Affected-proband genotype and phenotype documentation showing a known pathogenic WFS1 variant in trans.
  • Parental or offspring testing establishing phase for the candidate pathogenic allele.
Sources
PP4 ACMG_2015Not assessed: the case lacks a sufficiently specific patient phenotype or family history establishing a single genetic etiology for PP4. Details ▾Hide ▴
Reasoning

PP4 requires a patient's phenotype or family history that is highly specific for a disease with a single genetic etiology. The case evidence does not provide a sufficiently detailed phenotype or family history for the evaluated patient. PMID:34997062 describes hearing loss in a reported carrier of p.Glu776Val, but that phenotype is not established as highly specific for a single WFS1-related genetic etiology and the paper reports benign reanalysis; PMID:24909696 reports non-segregation with hearing impairment. The available information is insufficient to assess PP4 for this case.

Rule
Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology.
Evidence considered
  • No case-specific phenotype or family-history description sufficient for a PP4 determination was provided.
  • PMID:34997062 reports bilateral, moderate, progressive hearing loss in a carrier of p.(Glu776Val), but the phenotype is not shown to be highly specific for a single genetic etiology and the variant was reclassified as benign.
  • PMID:24909696 states that p.Glu776Val did not segregate with hearing impairment in the studied families.
Still missing
  • A documented patient phenotype and family history, including disease-specific features and differential diagnosis, are needed for PP4 assessment.
Sources
BS2 ACMG_2015Not assessed: gnomAD reports 31 homozygotes, but does not establish healthy-adult status, age, phenotypic evaluation, or early full penetrance. Details ▾Hide ▴
Reasoning

BS2 is not assessed. gnomAD reports 2 homozygotes in v2.1 and 31 homozygotes in v4.1, but the available population records do not establish that these were healthy adults, their ages, their phenotypic evaluations, or that full penetrance is expected at an early age for the relevant WFS1 disorder. Homozygote counts alone therefore do not satisfy the healthy-adult requirement of BS2.

Rule
Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age.
Evidence considered
  • gnomAD v2.1 reports 2 total homozygotes and gnomAD v4.1 reports 31 total homozygotes for the variant.
  • The gnomAD evidence provides aggregate allele and homozygote counts, but no individual-level health, age, or phenotype information sufficient to establish the BS2 healthy-adult condition.
Still missing
  • Individual-level evidence that homozygous carriers were healthy adults with adequate phenotype and age assessment.
  • Disease-specific confirmation that full penetrance is expected at an early age for the condition being evaluated.
Sources
BS3 ACMG_2015Not assessed: no variant-specific validated functional assay showing no damaging effect on WFS1 protein function or splicing was identified. Details ▾Hide ▴
Reasoning

No variant-specific validated in vitro or in vivo functional assay showing a normal protein-function or splicing result for NM_006005.3:c.2327A>T (NP_005996.2:p.(Glu776Val)) was identified in the reviewed evidence. PMID:26435059 was computational and did not mention the exact variant, while PMID:34997062 reported clinical sequencing and curation evidence without a functional assay. Absence of a damaging assay does not establish a benign functional result; therefore, BS3 remains not_assessed rather than met or not_met.

Rule
Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing.
Evidence considered
  • PMID:26435059, Discussion: the study used computational prediction and structural analyses of WFS1 nonsynonymous variants; it did not mention c.2327A>T or p.Glu776Val and reported no variant-specific functional assay.
  • PMID:34997062, Results/Variant curation and Table 2, WFS1 variant 17: the exact p.(Glu776Val) variant was reported from sequencing and curation data, with no functional assay demonstrating preserved protein function or splicing.
  • No reviewed source supplied a validated, reproducible, variant-specific in vitro or in vivo result showing no damaging effect on WFS1 protein function or splicing.
Still missing
  • No variant-specific in vitro or in vivo assay result was identified showing no damaging effect on protein function or splicing.
  • No assay validation, control performance, reproducibility data, or quantitative normal-function measurement is available for this variant.
Sources
BP2 ACMG_2015Not assessed: maternal inheritance alone does not show a pathogenic variant in trans for dominant disease or in cis in any inheritance pattern. Details ▾Hide ▴
Reasoning

BP2 cannot be assessed from the available evidence. The reported maternal inheritance of NM_006005.3:c.2327A>T (NP_005996.2:p.(Glu776Val)) does not demonstrate either a pathogenic variant in trans in a fully penetrant dominant disorder or a pathogenic variant in cis. No parental, offspring, or haplotype data identify a qualifying pathogenic allele in either phase configuration.

Rule
Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern.
Evidence considered
  • PMID:34997062, Table 2, WFS1 entry for p.(Glu776Val): maternal inheritance is reported, but no qualifying pathogenic variant in cis or in trans is identified.
  • PMID:24909696, abstract: p.Glu776Val did not segregate with hearing impairment in the studied families; this provides no cis/trans pathogenic-variant configuration for BP2.
Still missing
  • Documented pathogenic variant in trans in a fully penetrant dominant WFS1 disorder, or pathogenic variant in cis in any inheritance pattern.
  • Parental, offspring, or haplotype testing establishing the relevant phase.
Sources
BP5 ACMG_2015Not assessed: no exact-variant case with a demonstrated alternate molecular basis for the relevant disease was documented. Details ▾Hide ▴
Reasoning

BP5 requires the variant to be found in a case with an alternate molecular basis for disease. The available exact-variant reports do not document a case in which NM_006005.3:c.2327A>T co-occurs with a demonstrated alternative molecular diagnosis for the relevant disease. PMID:31638168 discusses other WFS1 variants and additional genes in different patients, but does not report this exact variant and cannot establish BP5 for it.

Rule
Variant found in a case with an alternate molecular basis for disease.
Evidence considered
  • No exact-variant case with a confirmed alternate molecular basis was identified in the reviewed evidence.
  • PMID:31638168 reports other WFS1 variants and additional variants in different patients; its extract explicitly states that p.(E776V) was not mentioned.
  • PMID:34997062 reports p.(Glu776Val) in a hearing-loss cohort but does not document an alternate molecular diagnosis for that case.
Still missing
  • An exact-variant case report with an independently established alternative molecular diagnosis is needed for BP5 assessment.
Sources
Not applicable · 4· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a missense variant. Details ▾Hide ▴
Reasoning

PVS1 (ClinGen SVI PVS1 recommendations, PMC6185798, pvs1_generic_framework) applies only to null variant classes — nonsense, frameshift, canonical ±1/2 splice-consensus, translation-initiation-codon loss, and stop-loss variants — each expected to trigger nonsense-mediated decay or otherwise abolish normal protein function. NM_006005.3:c.2327A>T in WFS1 is a missense substitution predicted to produce NP_005996.2:p.(Glu776Val). As a result, no null-variant mechanism (nonsense-mediated decay, truncation, or canonical splice disruption) is triggered by this variant class, so PVS1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PVS1 for WFS1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_null_variant_class
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
PM4 N/ANot applicable: PM4 requires a protein-length change, and this is a missense variant. Details ▾Hide ▴
Reasoning

PM4 (Richards et al. 2015, PMID:25741868) applies to protein length changes: in-frame insertions/deletions in a non-repetitive region, or stop-loss variants that extend the protein past the reference stop codon. NM_006005.3:c.2327A>T in WFS1 is a missense substitution predicted to produce NP_005996.2:p.(Glu776Val). As a result, no change in protein length occurs, so there is nothing for this criterion to evaluate, so PM4's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM4 for WFS1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_stop_loss_or_nonrepeat_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP3 N/ANot applicable: BP3 requires an in-frame indel in a repeat region, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP3 (Richards et al. 2015, PMID:25741868) applies to in-frame insertions/deletions located in a repetitive region without a known function. NM_006005.3:c.2327A>T in WFS1 is a missense substitution predicted to produce NP_005996.2:p.(Glu776Val). As a result, the variant does not alter protein length within a repeat region, so there is nothing for this criterion to evaluate, so BP3's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP3 for WFS1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_repeat_region_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_006005.3:c.2327A>T in WFS1 is a missense substitution predicted to produce NP_005996.2:p.(Glu776Val). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for WFS1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Identifiers

Gene
WFS1
Transcript
NM_006005.3
Coding (HGVS c.)
NM_006005.3:c.2327A>T
Protein (HGVS p.)
NP_005996.2:p.(Glu776Val)
GRCh38
chr4:6302122 A>T
GRCh37
chr4:6303849 A>T
Location and type
Exon 8 · missense
ClinVar
166606

Gene diagram

Every interpreted variant in WFS1, mapped onto the exon structure of NM_006005.3. Select a row to find it on the plot.

WFS1NM_006005.3
Fetching transcript structure from UCSC…
gnomAD v4.1 6,835 / 1,612,924 alleles AF 0.00424 · 31 homozygotes · FAF 0.00467
gnomAD v2.1 1,054 / 278,866 alleles AF 0.00378 · 2 homozygotes · FAF 0.00512
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 0.0042 · 6835 / 1,612,924 alleles · 31 hom · FAF 0.0047
European (Finnish)706 / 62,786 0.0118 hom
European (non-Finnish)5638 / 1,180,008 0.004817 hom
Remaining individuals262 / 62,494 0.00421 hom
Ashkenazi Jewish65 / 29,600 0.00221 hom
Admixed American54 / 60,030 0.00091 hom
South Asian61 / 91,088 0.000673 hom
African/African American49 / 75,066 0.00065
0 alternate alleles recorded in 3 other groups: Amish, East Asian, Middle Eastern.

gnomAD v2.1

AF 0.0038 · 1054 / 278,866 alleles · 2 hom · FAF 0.0051
European (Finnish)256 / 25,086 0.011 hom
European (non-Finnish)675 / 126,192 0.00531 hom
Remaining individuals27 / 7,178 0.0038
Ashkenazi Jewish16 / 10,260 0.0016
African/African American27 / 24,408 0.0011
South Asian25 / 30,580 0.00082
Admixed American28 / 35,370 0.00079
0 alternate alleles recorded in 1 other group: East Asian.

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 0.00423765; MAF= 0.42376%, 6835/1612924 alleles, homozygotes = 31) and has highest observed frequency in the European (Finnish) population (AF= 0.0112445; MAF= 1.12445%, 706/62786 alleles, homozygotes = 8); grpmax FAF= 0.0046733.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 0.00377959; MAF= 0.37796%, 1054/278866 alleles, homozygotes = 2) and has highest observed frequency in the European (Finnish) population (AF= 0.0102049; MAF= 1.02049%, 256/25086 alleles, homozygotes = 1); grpmax FAF= 0.00511863.

gnomAD-Canada

Not available in gnomAD-Canada v1.0.

SpliceAI and Pangolin

SpliceAI acceptor lossat +97 bp
0.000
SpliceAI acceptor gainat +25 bp
0.001
SpliceAI donor lossat +253 bp
0.000
SpliceAI donor gainat -6 bp
0.000
Pangolin splice lossmagnitude shown
-0.002
Pangolin splice gain
0.002

Other predictors

REVEL
0.981
BayesDel
0.517

How the predictions were used

PP3 StrongACMGMet, strong: missense REVEL score 0.981 exceeds the generic PP3 strong threshold of 0.932. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, so the generic PP3 missense path uses REVEL only; SpliceAI and BayesDel are not used for this criterion. REVEL is 0.981, meeting the supplied generic PP3 strong threshold of >= 0.932 from the ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet, PMID:36413997). This supports PP3 at strong strength without double-counting additional computational predictors.

Rule
PP3: Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.).
Evidence considered
  • Variant consequence: missense, NP_005996.2:p.(Glu776Val); therefore the applicable generic PP3 path is REVEL only.
  • Local REVEL lookup reports score 0.981 for NM_006005.3:c.2327A>T (source_registry key: revel).
  • Generic calibration: PP3 strong requires REVEL >= 0.932 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet), PMID:36413997.
  • SpliceAI max delta is 0.001 and BayesDel is 0.51747, but neither is used because this is a missense variant and the governing generic path requires REVEL only.
Sources
revel
BP4 ACMGNot met: REVEL 0.981 is above the generic BP4 supporting threshold of 0.29, so it does not indicate a tolerated missense change. Details ▾Hide ▴
Reasoning

The variant is a missense change, so BP4 must use the REVEL path only. REVEL is 0.981, which is above the generic BP4 supporting threshold of <= 0.29 and therefore does not support no impact. The SpliceAI max delta of 0.001 is not used for BP4 because no-predicted-splice-impact is not BP4 evidence for a missense variant; BayesDel is not available for generic ACMG strength assignment.

Rule
Missense variant -> REVEL only. Its SpliceAI score says nothing about whether the amino-acid substitution is tolerated, so 'no predicted splice impact' is never BP4 support for a missense variant. BP4 (supporting): <= 0.29 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • NM_006005.3:c.2327A>T is a missense variant, so BP4 uses REVEL only.
  • Local REVEL lookup reports a score of 0.981 for this variant.
  • The generic BP4 supporting threshold is <= 0.29, from the ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet; PMID:36413997).
  • SpliceAI max delta 0.001 was not substituted for the missense REVEL result, and BayesDel 0.51747 is not available for generic ACMG-strength assignment.
Sources
revel
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_006005.3:c.2327A>T in WFS1 is a missense substitution predicted to produce NP_005996.2:p.(Glu776Val). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for WFS1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00). REVEL score = 0.981. BayesDel score = 0.51747.

6 paper records listed. 2 cited in the classification. None of the listed paper records explicitly indicates that the variant is named.

Cited in the classification

  • WFS1 mutations in hearing-impaired children.
    The PubMed abstract states that p.Glu776Val did not segregate with hearing impairment in the studied families, providing variant-specific evidence against co-segregation and supporting lack of segregation.
    → BS4 · strong Names this variant
    PMID 24909696 ↗
    Source detail
    The other two rare variants, p.Glu385Lys and p.Glu776Val, did not segregate with HI in the families.

    Location Abstract; detailed pedigree in family C

    Context Variant-focused study of hearing-impaired families; the abstract reports family segregation analysis, with the detailed pedigree identified as family C.

  • Predicting pathogenicity for novel hearing loss mutations based on genetic and p
    The paper explicitly reports WFS1 c.2327A>T, p.(Glu776Val), and states that the variant changed from conflicting interpretation to benign after reanalysis.
    → BS4 · strong Names this variant
    PMID 34997062 ↗
    Source detail
    Interestingly, two variants changed from conflicting interpretation to benign after reanalysis [p.(Lys41Glufs*113) in DFNA5 and p.(Glu776Val) in WFS1]

    Location Results, Variant curation; Table 2, WFS1 entry (variant 17)

    Context Whole-exome sequencing of 32 patients evaluated using a 183-gene hearing-loss panel, followed by Sanger confirmation, segregation analysis when available, and ACMG/Hearing Loss Expert Panel curation.

Other recorded publications

  • A systematic approach to assessing the clinical significance of genetic variants.
    Duzkale H et al. · 2013
    No paper-specific finding is recorded.
    PMID 24033266 ↗
  • Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
    Richards S et al. · 2015
    No paper-specific finding is recorded.
    PMID 25741868 ↗
  • Genetic Hearing Loss Overview.
    Adam MP et al. · 1993
    No paper-specific finding is recorded.
    PMID 20301607 ↗
  • WFS1 Spectrum Disorder.
    Adam MP et al. · 1993
    No paper-specific finding is recorded.
    PMID 20301750 ↗
  • Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.
    Nykamp K et al. · 2017
    No paper-specific finding is recorded.
    PMID 28492532 ↗
  • Expert specification of the ACMG/AMP variant interpretation guidelines for genetic hearing loss.
    Oza AM et al. · 2018
    No paper-specific finding is recorded.
    PMID 30311386 ↗

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 0.00423765; MAF= 0.42376%, 6835/1612924 alleles, homozygotes = 31) and has highest observed frequency in the European (Finnish) population (AF= 0.0112445; MAF= 1.12445%, 706/62786 alleles, homozygotes = 8); grpmax FAF= 0.0046733.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 0.00377959; MAF= 0.37796%, 1054/278866 alleles, homozygotes = 2) and has highest observed frequency in the European (Finnish) population (AF= 0.0102049; MAF= 1.02049%, 256/25086 alleles, homozygotes = 1); grpmax FAF= 0.00511863.

gnomAD-Canada

Not available in gnomAD-Canada v1.0.

ClinVar

This variant has been reported in ClinVar as Likely benign (10 clinical laboratories) and as Benign (6 clinical laboratories) and as Likely Benign (1 clinical laboratory). (ClinVarID = 166606)

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00). REVEL score = 0.981. BayesDel score = 0.51747.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.